Skip to content
TheChatArchiveThe Chat Archive
Claudeclaude-3-7-sonnet-20250219-thinking-32k· AnthropicHugging Face Arena Expert 5K

4.1.2利用 iPSC 衍生物模拟神经退行性疾病

  1. User

    4.1.2利用 iPSC 衍生物模拟神经退行性疾病

  2. Claude Assistant

    4.1.2 iPSC-derived Models of Neurodegenerative Diseases

    译注: 我已将章节标题按照Nature/Cell风格翻译。如需翻译整个4.1.2小节内容,请提供原文文本。


    如果您需要扩展这一章节,以下是建议的内容组织框架:

    典型的Nature/Cell风格章节会包含:

    1. 开篇概述 - 神经退行性疾病建模的挑战和iPSC技术的独特优势
    2. 关键疾病模型 - 简要总结阿尔茨海默病、帕金森病、亨廷顿病等iPSC模型
    3. 技术创新 - 如3D培养、神经-胶质共培养、老化诱导等
    4. 临床相关性 - iPSC模型如何促进药物发现和个体化治疗
    5. 局限与展望 - 当前挑战与未来方向

    这种结构既保持了科学严谨性,又符合高影响因子期刊的叙事风格——先阐述问题,再介绍解决方案,最后指出前景。

    需要我为这一章节起草具体内容吗?或者您有相关原文需要翻译成Nature/Cell风格的英文?

  3. User

    干邑这句话就好

  4. Claude Assistant

    已完成章节标题翻译:

    4.1.2 iPSC-derived Models of Neurodegenerative Diseases

    这个标题已经符合Nature/Cell期刊风格要求—简洁、专业且直接。如果您有正文内容需要翻译,或需要我协助其他部分,请随时告知。

  5. User

    神经退行性疾病(如阿尔茨海默病、帕金森病、亨廷顿舞蹈症、肌萎缩侧索硬化症等)是一类以特定神经元群体逐渐丧失和神经功能障碍为特征的慢性进行性脑部疾病,严重威胁老年人群的健康,随着社会老龄化问题愈发严重,该类疾病也给社会带来了极大的经济负担102。神经退行性疾病的影响因素除了各种突变和遗传外,衰老是此类疾病的一个重要风险因素,并且与其进展的分子机制紧密相关。iPSC衍生的细胞类似于胎儿,不会自然表现出与衰老相关的表型103,104。因此,iPSC技术的研究最初侧重于生成和分析具有明显基因突变的单基因家族性疾病的病理模型105。该类突变具有高度渗透性,并在iPSC衍生细胞的分子和细胞表型中清晰地变现出来。例如,携带SNCA基因突变的多巴胺能神经元表现出帕金森病(PD)特有的 α-突触核蛋白聚集;携带TDP-43基因突变的运动神经元表现肌萎缩侧索硬化症(ALS)特有的 TDP-43 聚集106,107。尽管大多数神经退行性疾病病例是散发性的,没有明确的病因,iPSC技术仍可用于分析由衰老和环境因素等各种机制引起的散发性疾病的发病机制,以及外显率低的复杂遗传学105。目前,全基因组关联研究(GWAS)已经成功识别出许多与复杂疾病相关的遗传变异,包括单核苷酸多态性(SNP)108;并且可以使用 iPSC 衍生细胞模拟它们对疾病进展的微妙影响。通过在iPSC中创建基因组编辑的回复突变并分析其表型,能够检测这些功能意义未知的SNP的基因型和表型之间的因果关系105。例如,源自散发性 ALS 患者 iPSC 的运动神经元根据其异质性表型聚集成不同的组,这说明了 iPSC 衍生细胞模型在改善患者分层方面的应用109。基于 iPSC 的深度表型分析已被证明可用于对属于同一诊断类别但已知具有不同病理和药物反应的疾病进行分层109,110

  6. Claude Assistant

    4.1.2 iPSC-derived Models of Neurodegenerative Diseases

    Neurodegenerative diseases—including Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis—are chronic progressive brain disorders characterized by the selective loss of specific neuronal populations and consequent functional deficits. These conditions pose a significant threat to the aging population and, amid demographic shifts toward an increasingly elderly society, impose substantial economic burdens[^102].

    While various mutations and genetic factors contribute to neurodegenerative pathology, aging remains a critical risk factor intimately linked to the molecular mechanisms of disease progression. Notably, iPSC-derived cells resemble fetal tissue and do not naturally exhibit aging-associated phenotypes[^103,104]. Consequently, early iPSC research primarily focused on generating and analyzing pathological models of monogenic familial diseases with distinct genetic mutations[^105]. These mutations exhibit high penetrance and manifest clearly as molecular and cellular phenotypes in iPSC-derived cells. For instance, dopaminergic neurons carrying SNCA mutations display the α-synuclein aggregation characteristic of Parkinson's disease (PD), while motor neurons with TDP-43 mutations recapitulate the TDP-43 aggregation typical of amyotrophic lateral sclerosis (ALS)[^106,107].

    Despite the predominance of sporadic cases with no clear etiology in most neurodegenerative disorders, iPSC technology provides valuable insights into disease mechanisms driven by various factors including aging and environmental influences, as well as those with complex genetics and low penetrance[^105]. Genome-wide association studies (GWAS) have successfully identified numerous disease-associated genetic variants, including single nucleotide polymorphisms (SNPs)[^108], whose subtle effects on disease progression can now be modeled using iPSC-derived cells. Creating genome-edited reversion mutations in iPSCs and analyzing the resulting phenotypes enables detection of causal relationships between genotype and phenotype for SNPs with previously unknown functional significance[^105].

    Motor neurons derived from sporadic ALS patients' iPSCs, for example, cluster into distinct groups based on their heterogeneous phenotypes, demonstrating the utility of iPSC-derived cellular models in improving patient stratification[^109]. iPSC-based deep phenotypic analysis has proven effective in stratifying diseases within the same diagnostic category but with known differences in pathology and drug responses[^109,110].


    翻译特点分析

    1. 结构优化:

      • 将原文整理为四个关键段落,按主题逻辑排列:介绍→技术特点→应用示例→前景应用
      • 各段落首句点明核心观点,符合Nature/Cell的"clear first sentence"原则
    2. 语言精炼:

      • 将"一类以特定神经元群体逐渐丧失和神经功能障碍为特征的慢性进行性脑部疾病"简化为"chronic progressive brain disorders characterized by the selective loss of specific neuronal populations and consequent functional deficits"
      • "创建基因组编辑的回复突变并分析其表型"转化为更专业的表达"Creating genome-edited reversion mutations in iPSCs and analyzing the resulting phenotypes"
    3. 专业术语规范:

      • 保留基因斜体格式:SNCA, TDP-43
      • 使用标准缩写:GWAS, SNPs, ALS, PD等
    4. 强调因果关系:

      • "enables detection of causal relationships"强调了技术的核心优势
      • "demonstrating the utility"直接点明应用价值

    以上翻译保持了科学准确性,同时采用了更符合Nature/Cell期刊风格的表达方式。

Responses were produced in different, uncontrolled contexts (system prompts, settings, prior turns). This is not a benchmark.